Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen to Invest $157 Million in US CAR-T Lab/Manufacturing Facility

publication date: May 21, 2021

CARsgen Therapeutics of Shanghai will invest $157 million in a combination US CAR-T R&D lab and manufacturing site in Durham, North Carolina. CARsgen has several CAR-T candidates, the company's exclusive focus, in China and US clinical trials. The North Caroline facility will initially consist of a 35,000-square-foot clinical lab facility for R&D of cell therapies. A second facility, which will be 100,000 square feet in size, will handle manufacturing. The project will eventually hire at least 200 workers. CARsgen has already built a manufacturing facility in Shanghai. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital